Please login to the form below

Eliquis

This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

BMS’ Opdivo defies naysayers with healthy growth

Outside oncology, BMS’top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and
Xarelto no better than aspirin in secondary stroke study

For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s ... This year saw a reversal of fortune however, with
Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

On the plus side, the firm reported solid growth for other newer products such as breast cancer drug Ibrance (palbociclib) and oral anticoagulant Eliquis (apixaban), up 66% to $853m and 50%
Xarelto beats aspirin for recurrent blood clots

rival NOAC Eliquis (apixaban) from Pfizer and Bristol-Myers Squibb (BMS) with 42.5%, well ahead of third place Pradaxa (dabigatran) from Boehringer Ingelheim and Daiichi Sankyo's new entrant Savaysa ... edoxaban). Xarelto has slipped from a 60%-plus
Opdivo drives growth at BMS, but US sales slow down

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

More from news
Approximately 19 fully matching, plus 80 partially matching documents found.

The good, the bad and the ugly

This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.
Modern anticoagulants threaten status quo

Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PPD expands global product department with new therapeutic area heads

Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

No results were found

Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...